Answers are grounded in this paper and cite their sources.
The persistence of latent reservoirs remains the primary barrier to HIV-1 eradication. Although diverse latency-reversing agents (LRAs) have been designed to induce latent HIV-1 expression, their clinical utility is frequently limited by significant toxicity or insufficient potency. Our previous research confirmed that resveratrol reverses latent HIV-1 expression in vitro by regulating multiple signaling pathways. Based on the chemical structure of resveratrol, we designed and synthesized a small-molecule compound, XQ2 (5,7-dimethoxy-2-[5-(Ethoxymethyl)-2-furanyl]-4-(3H)-quinazolinone). Current data indicate that XQ2 efficiently promotes viral reactivation in latently infected cell models while maintaining low cytotoxicity and avoiding broad T-cell stimulation. Significantly, XQ2 demonstrates synergistic potential when administered alongside several typical LRAs. The mechanism driving XQ2-mediated reactivation appears to involve the release of positive transcription elongation factor b (P-TEFb) from bromodomain 4 (BRD4), facilitating Tat-dependent viral transcription. These results suggest that XQ2 is a promising, low-toxicity LRA candidate for advancing the "shock and kill" eradication strategy.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: